APA (7th ed.) Citation

Ganguly, S., Cortes, J. E., Krämer, A., Levis, M. J., Martinelli, G., Perl, A. E., . . . Khaled, S. K. (2021). Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial. Transplantation and cellular therapy, 27(2), . https://doi.org/10.1016/j.bbmt.2020.09.036

Chicago Style (17th ed.) Citation

Ganguly, Siddhartha, et al. "Clinical Outcomes in Patients with FLT3-ITD-mutated Relapsed/refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial." Transplantation and Cellular Therapy 27, no. 2 (2021). https://doi.org/10.1016/j.bbmt.2020.09.036.

MLA (9th ed.) Citation

Ganguly, Siddhartha, et al. "Clinical Outcomes in Patients with FLT3-ITD-mutated Relapsed/refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial." Transplantation and Cellular Therapy, vol. 27, no. 2, 2021, https://doi.org/10.1016/j.bbmt.2020.09.036.